Ligand Pharma (LGND) Tops Q3 EPS by 50c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.84, $0.50 better than the analyst estimate of $1.34. Revenue for the quarter came in at $51.81 million versus the consensus estimate of $40.6 million.
GUIDANCE:
Ligand Pharma sees FY2024 EPS of $5.50-$5.70, versus the consensus of $5.39. Ligand Pharma sees FY2024 revenue of $160-165 million, versus the consensus of $156.3 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
